Polymerase chain reaction sequence-specific oligonucleotide is commonly used for HLA-typing. We replaced our LabType SSO HD (HD) kits with LabType SSO XR (XR) kits (One Lambda, Inc., Canoga Park, California) for HLA-A, -B, and -DRB1 following acquisition of a LABScan3D analyzer. The XR kits have more bead regions than the HD kits, allowing for an extended number of probes and exon coverage. They are claimed to improve typing resolution and to diminish the number of allele ambiguities, including common and well-documented (CWD) and null alleles to be resolved. We retrospectively selected patients who had their first HLA-typing performed with the HD kits and their second determination with the XR kits between 2015 and 2016. Forty-two patients were selected for HLA-A typing comparison, and 48 for HLA-B and 41 for HLA-DRB1. XR kits significantly decreased the number of allele ambiguities for HLA-A and -B. On the other hand, the improvement was limited for the HLA-DRB1 locus. The XR kits did not resolve all the CWD HLA allele ambiguities, which may be important for organ and/or hematopoietic stem cell transplantations. The XR kits eliminated 88%, 62%, and 27% of null allele ambiguities for HLA-A, -B, and -DRB1 loci, respectively. In conclusion, the XR kits allow for a significant improvement of HLA-typing resolution for HLA-A and -B loci in comparison with HD kits. In contrast, the number of oligonucleotides in the XR HLA-DRB1 kit should be extended to include exon 3 at the very least. It could also be interesting to include oligonucleotides allowing HLA-DRB3, 4, and 5 typing.
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| INTRODUCTION
HLA genes are the most polymorphic of human genome with 17 695 HLA alleles assigned as of December 2017 in the IPD-IMGT/HLA Database. 1 It has been extensively studied because of its outstanding importance in transplantation [2] [3] [4] [5] and its association with autoimmune, infectious, inflammatory diseases, and cancers. [6] [7] [8] [9] [10] In solid-organ transplantation, HLA matching between donors and recipients is an important parameter impacting graft survival. 2, 3 Consequently, HLA-typing is required in pretransplant evaluation. This is especially true in kidney transplantation that includes HLA matching as a part of the attribution scores in the national transplant allocation programs. 11 Donor and recipient HLA-typing is also essential in pre-and post-transplant monitoring in order to precisely identify donor-specific antibodies (DSA). Indeed, preformed and de novo DSA are associated with graft Jonathan Visentin and Gwendaline Guidicelli contributed equally to this study.
rejection, dysfunction, and loss. [12] [13] [14] [15] [16] [17] [18] The link between DSA and graft outcomes has been particularly emphasized because the development of Single Antigen Flow Beads assays that, for now, allows humoral reactivity against around 200 class-I and -II HLA antigens to be studied. It is noteworthy that DSA can recognize amino acid (a.a) modifications on surface accessible positions of HLA molecules, named by Duquesnoy et al 19, 20 as "eplets." Furthermore, a recipient having a null allele can develop DSA against other antigens belonging to the same group of this allele. 21 Historically, HLA-typing has been performed using complement-dependent cytotoxicity (CDC) assays, 22 especially in the organ transplantation setting. Its accuracy was acceptable for HLA-A, -B, and -DR typing as it matched to the assays concomitantly used for HLA antibody detection. HLA-DQ typing, however, was challenging, and HLA-Cw and -DP typing were unavailable. The need for a complete and more precise HLA-typing arose with our understanding of antibody-mediated rejection, a direct result of improvements in HLA antibody assays. Indeed, several authors have described that DSA directed against HLA-C and -DP can be of clinical importance, and that patients can develop "allelespecific" (two-field resolution) sensitization. [23] [24] [25] As a consequence, HLA-typing is now preferentially performed with more precise molecular methods such as sequence-specific oligonucleotide (SSO) probe hybridization, sequencespecific primer amplification, sequence-based typing, or more recently next-generation sequencing (NGS). 26 These methods provide results from low, high to allelic typing resolution. In order to fulfill the requirements for solid-organ transplantation, reagent manufacturers developed assays with an "intermediate resolution" level, allowing some of the most common alleles of the same group (first field) to be discriminated. For that purpose, SSO is the most commonly used assay. [26] [27] [28] However, the length of ambiguity strings (lists of alleles and possible genotypes consistent with the typing data) is inexorably increasing as new alleles are added to the IPD-IMGT/HLA Database. Therefore, generating and interpreting probe reactivity patterns of SSO have become a challenge. In hematopoietic stem cell transplantation (HSCT), high typing resolution is required for donors and recipients as HLA identity at the level of peptide presentation is of primary importance for engraftment, graft-versushost disease occurrence, and overall survival. 4 Indeed, a.a changes in the HLA peptide binding groove lead to a strong alloreactivity. [29] [30] [31] Moreover, the development of haplo-identical transplantations has increased the importance of anti-HLA sensitization before the graft, leading to shared compatibility rules with organ transplantation. 32, 33 For HSCT, NGS typing is now widely used;
however, SSO is still a useful screening method, for example, when a geno-identical donor is searched among recipient's siblings. 5 Several kits are available to carry out SSO. Our laboratory used the One Lambda PCR-LABType SSO HD (HD) kits for several years and recently changed to the new PCR-LABType SSO XR (XR) kits for HLA-A, -B, and -DRB1 typing that require the new LABScan3D analyzer. This analyzer is able to read a higher number of different beads, up to 500 vs the 100 able to be read by previous ones. This allows the number of SSOs and covered exons to be extended.
The aim of this study was to evaluate the improvement in HLA-typing provided by XR kits in comparison with HD kits. We expected the XR kits would decrease the number of ambiguities and unresolved null alleles.
| METHODS

| HLA-typing
HLA genotyping of HLA-A, -B, and -DRB1 loci were performed by the SSO method combined with Luminex technology (Luminex Corp., Austin, Texas), as described previously, obeying manufacturer recommendations. 34, 35 Two types of kits were compared: the HD kits analyzed with a Luminex LABScan100IS system vs the XR kits analyzed with the LABScan3D system (One Lambda, Inc.). For the main analysis performed in Bordeaux's laboratory, the HD kits included 1081, 1112, and 449 different oligonucleotide probes, respectively, for HLA-A, -B, and -DRB1 typing. They used 100 different beads covering exon 2 and 3 for HLA-A and B loci and exon 2 for HLA-DRB1 locus. The XR kits included 1308, 1301, and 480 different oligonucleotide probes for HLA-A, -B, and -DRB1 typing, respectively. The XR kits were coated on 500, 485, and 384 different beads, respectively, and covered exons 2, 3, 4, and 5 for class I and exon 2 for class II. The assignment of HLAtyping was realized with HLA Fusion software (One Lambda, Inc.). The HD and XR catalogs used were as follows: RSSOH1A_009_04 (lot 009), RSSOH1B_008_04 (lot 008), RSSOH1B_009_02 (lot 009), and RSSOH2B1_009_06
(lot 009) for HD kits, RSSOX1A_002_02 (lot 002), RSSOX1B_004_01 (lot 004), and RSSOX2B1_004_01 (lot 004) for XR kits. The IPD-IMGT/HLA Database version imposed by the catalogs at the time of the analysis was the 3.21.1. A secondary analysis was performed in order to confirm the results with a more recent IPD-IMGT/HLA Database (3.27.1). We searched for similar HLA-A, -B, and -DRB1 most likely alleles combinations studied in the main analysis obtained in Bordeaux's laboratory with XR kits lots 2, 5, and 4, respectively, and in Poitiers's or Limoges's laboratory with HD kits lots 10 (for all loci).
| Data collection
For the main analysis, from March to April, Bordeaux's laboratory progressively switched from the HD to the XR kits. We retrospectively selected patients who had their first HLA-typing determination performed with the HD kits from September 2015 to January 2016, and their second determination typed for at least one locus with XR kits from January to August 2016. The results were extracted from the laboratory database. For the comparison of the HD and XR kits, the most likely common allele (according to the IPD-IMGT/ HLA Database) was depicted in all the tables, and the ambiguous alleles were compared with this allele through sequence alignment (IPD-IMGT/HLA Database). The comparison was made between the exons 1,2,3,4, and 5 in all loci. Therefore differences were detectable even if the exons are not covered by the polymerase chain reaction SSO. The common and well-documented (CWD) HLA alleles were determined with the last version of CWD catalogue. 36 
| Sequence alignment and structural analysis tools
Amino acid sequence alignments were performed with the IPD-IMGT/HLA database sequence alignment tool (http:// www.ebi.ac.uk/ipd/imgt/hla/align.html). Residue localization and antibody accessibility were evaluated with the "space fill" command of the Cn3D structure software program 37 using HLA-A*02:01, HLA-B*52:01, or HLA-DRB1*01:01 as a model downloaded from "Entrez Molecular Modeling Database" on the National Center for Biotechnology Information website (http///www.ncbi.nlm.nih.gov/Structure). HLA-A, -B, and -DRB1 eplets were retrieved from HLAMatchmaker. 38, 39 3 | RESULTS
| Improvement in HLA-A locus typing
The HLA-typing of 42 patients (84 alleles) were compared using HD and XR HLA-A kits, using the 3.21.1 version of the IPD-IMGT/HLA Database. The number of ambiguities unresolved by each kit for exons 1, 2, 3, 4 and 5 is depicted in Figure 1A . The total number of ambiguities for exons 2, 3, 4, and 5 was 549, 572, 1350, and 14, respectively, with the HD kit vs 176, 200, 60, and 14 with the XR kit. No ambiguity was found for exon 1. The mean decrease of ambiguity number with the XR kit was 68%, 66%, and 96% for exons 2, 3, and 4, respectively. No difference was observed in exon 5. Depending on the HLA-A allele, the ambiguity reduction ranged from 57% to 100%, as shown in Table 1 . A total of 17 allele combinations (among 28 initially analyzed) were reanalyzed with more recent reagent lots and IPD-IMGT/HLA Database version (3.27.1) (Table S1 in Appendix S1). We observed a significant increase in the number of ambiguities for both HD (155%) and XR (375%) kits. The reduction of ambiguities through the use of XR kit was still significant (58% reduction).
| Improvement in HLA-B locus typing
The HLA-typing of 48 patients (96 alleles) was compared using HD and XR HLA-B kits, using the 3.21.1 version of the IPD-IMGT/HLA Database. The number of ambiguities unresolved by each kit for exons 1, 2, 3, 4 and 5 is depicted in Figure 1B . The total number of ambiguities for exons The mean decrease in ambiguity number with the XR kit was 32%, 52%, 43%, 90%, and 95% for exons 1, 2, 3, 4, and 5, respectively. The results for each individual allele are shown in Table 2 . Unlike HLA-A, the reduction of ambiguity number was heterogeneous depending on the HLA-B alleles considered. Indeed, some alleles, for example, B*15:03, B*27:02, B*38:01, and B*41:01, had no reduction while others alleles, for example, B*40:01 or B*44:03, had more than 90% of their ambiguities resolved. A total of 21 allele combinations (among 42 initially analyzed) were reanalyzed with more recent reagent lots and IPD-IMGT/ HLA Database version (3.27.1) (Table S2 in Appendix S1). We observed a significant increase in the number of ambiguities for both HD (157%) and XR (256%) kits. The reduction of ambiguities through the use of XR kit was still significant (46% reduction).
| Improvement in HLA-DRB1 locus typing
The HLA-typing of 41 patients (82 alleles) was compared using HD and XR HLA-DRB1 kits, using the 3.21.1 version of the IPD-IMGT/HLA Database. The number of ambiguities unresolved by each kit for exons 1, 2, 3, 4, and 5 is depicted in Figure 1C . The total number of ambiguities for exons 1, 2, 3, and 5 was 6, 689, 53, and 3, respectively, with the HD kit vs 6, 570, 53, and 3 with the XR kit. No ambiguity was found for exon 4. The mean decrease of ambiguity number with the XR kit was 17% for exon 2, while none of the ambiguities were resolved for exons 1, 3, 4, and 5. The results for each individual allele are shown in Table 3 . In contrast to class I HLA, the reduction of ambiguity number was very low and only for exon 2. As a consequence, half of the HLA-DRB1 ambiguity lists were similar with both kits. The others showed a heterogeneous reduction of ambiguity number from 7% to 100%. A total of 14 allele combinations (among 33 initially analyzed) were reanalyzed with more recent reagent lots and IPD-IMGT/HLA Database version (3.27.1) (Table S3 in Appendix S1). We observed an increase in the number of ambiguities for both HD (152%) and XR (158%) kits. The reduction of ambiguities through the use of XR kit was limited (17% reduction).
| Resolution of CWD ambiguities
Each allele ambiguity was classified as a CWD allele or not, according to the European Federation for Immunogenetics (EFI) and American Society for Histocompatibility and Immunogenetics (ASHI) catalogs. 36, 40 A total of 24 CWD ambiguities were identified with the use of HD kits (10 HLA-A, 11 HLA-B, and 3 HLA-DRB1) ( Table 4 ). Among them, 9 (90%), 4 (36%), and none were resolved with XR kits, respectively, while all the CWD null alleles were resolved.
We assessed changes in a.a. positions between the most likely allele and CWD allele ambiguities in order to evaluate their potential clinical impact in organ transplantation and/or HSCT, regarding DSA production, engraftment, and graftversus-host disease. 20, 41, 42 Among the 20 CWD allele ambiguities which may be of clinical importance, 12 (60%) were resolved while 8 (40%) remained.
| Resolution of null alleles
The number of null alleles unresolved by each kit for the three loci were analyzed (Figure 2 ). HLA-A typing showed a high number of null alleles with the HD kit, which were frequently resolved by the XR kit: 364 null alleles vs 43 (88% reduction). The number of unresolved HLA-B null alleles with the HD kit was lower than for HLA-A, that is, 100. Among them, only 38 remained using the XR kit, corresponding to a 62% reduction of unresolved null alleles. On the other hand, the resolution of null alleles with the XR kit was less efficient for the HLA-DRB1 locus: 52 null alleles vs 38 (27% reduction).
| DISCUSSION
To our knowledge, this retrospective study is the first to explore improvements in HLA-A, -B, and -DRB1 typing through the use of new SSO XR kits in comparison with HD kits. As HLA-typing with both kits was needed, we took advantage of first and second determinations for our patients. These analyses are generally performed a few months apart, which explain the short inclusion period and small cohort size. However, despite the low number of patients studied, the distribution of HLA alleles in our cohort was still representative of the clinical practice. Indeed, the sum of the frequency of the most likely alleles we identified represented at least 90% of the European population according to Maiers et al 43 (data not shown). The same study should have been extended to the HLA-C XR kit, but it was Abbreviations: a.a., amino acid; CWD, common and well-documented; NA, not applicable.
FIGURE 2
Number of null allele ambiguities for HLA-A, HLA-B, and HLA-DRB1 typing. The sum of null allele ambiguities unresolved with HD kits is in dark gray, with XR kits in light gray not possible in our laboratory as HLA-C is only typed once per patient. Noteworthy, the method used by XR kits is the same as HD kits, it does not take longer, and we did not observed a higher failure rate of typing. We showed that the XR kits resolve a significant number of allele ambiguities for HLA-A, HLA-B typing, but to a lower extent for HLA-DRB1 locus. The XR kit is one of the most significant improvements of SSO provided by One Lambda, because of the transition from low to intermediate resolution, when the HD kits became available in 2008. At that time, the strategy was to slightly increase the number of beads and to use several probes on some beads. However, the number of remaining ambiguities, CWD, or null alleles dramatically varied depending on the locus, the subset of alleles, and the exons concerned. The development of Luminex 3D supported the improvement of SSO typing kits through a 5-fold increase in the number of bead regions available. Of note, in the main analysis, the IPD-IMGT/HLA Database used was the 3.21.1 (July 2015). Thus, we repeated the analysis with more recent reagent lots and database 3.27.1 (January 2017). Interestingly, we observed that the increase in ambiguity number did not change our observed trends regarding improvement in HLA-typing through use of XR kits.
The HLA-A and -B XR kits use efficiently the Luminex 3D technology by incorporating 500 and 485 bead regions with 227 and 189 additional oligonucleotides probes, respectively. As an example, the number of ambiguities of the most likely typing result HLA-A*02:01, widely represented in the population, is decreased by 87%. But, it is mostly because of exon 4, the remaining 5 to 6 ambiguities per typing occurring in exons 2 and 3. Interestingly, we observed the resolution of some ambiguities in exon 1 for the common typing result B*40:01. It was possible because of alleles having polymorphisms both in exons 1 and 4. In contrast to the class I locus, the performance of the HLA-DRB1 XR kit was disappointing. Indeed, it only allowed a decrease in ambiguity number by 17%. It was not surprising as this study was only covering exon 2 with 384 different beads regions and 31 additional oligonucleotides probes. The remaining 118 possible different beads could be used to at least include exon 3, in order to discriminate alleles differing in their a.a. sequence at the extracellular part of the molecule. It would also be interesting to include probes to type the HLA-DRB3, -DRB4, and -DRB5 loci.
We attached importance to the analysis of the remaining ambiguities corresponding to CWD alleles, and their potential clinical relevance by analyzing the differing a.a. from the most likely common alleles. Before performing a transplant, calculating the degree of eplet mismatching of a donor for a recipient, that is, the eplet load, is possible by using specifically designed computer programs such as HLAMatchmaker. Although it has not been widely integrated in the current clinical practice, it may become an essential tool as several studies have shown significant correlations between the eplet load and the development of DSA as well as rejection incidence and allograft outcome. [44] [45] [46] More recently, the Predicted Indirectly ReCognizable HLA Epitopes (PIRCHE-II) presented by HLA-DRB1) algorithm, which determines differences between donor and recipient HLA-derived Thelper epitopes, was proposed to estimate the risk of transplant outcome. 47 Indeed, PIRCHE-II correlated with de novo DSA development after kidney, pancreas, and islet transplantation [47] [48] [49] and will benefit from future improvements. 50, 51 Because a precise determination of eplet load and PIRCHE-II requires complete HLA-typing at a two-field resolution for both donor and recipient, the improvement in HLA-typing by the XR kits is completely in tune with these emerging approaches. Compared with the large number of CWD alleles described in EFI and ASHI catalogs, the CWD resolution of the XR kit is quite satisfactory. Importantly, this CWD analysis could be less informative in minority ethnicities. The reagent manufacturer also proposes "CWD" kits, which we did not test. One might anticipate that these kits resolve most of CWD allele ambiguities, while leaving more ambiguities with rare alleles. We also analyzed raw patterns of HD and XR kits in order to evaluate their capacity to discriminate alleles available on the Single Antigen Bead panels used by HLA laboratories, including the two reagents providers (One Lambda, Inc., and Immucor, Norcross, Georgia). Interestingly, HD kits already discriminated these alleles but DRB1*14:01 vs DRB1*14:54 ambiguity is not resolved by XR kits (Tables S4 and S5 in Appendix S1).
Finally, the XR kit allowed the number of null alleles to be greatly reduced. This is critically important, as it precludes the need for additional assays, such as CDC, for their resolution. Indeed, regarding the donor, misidentifying a null allele induces high risk for graft-versus-host disease in HSCT. In solid-organ transplantation, a recipient null allele can confuse the interpretation of HLA antibody profiles and graft allocation, while a donor null allele is a chance for a highly sensitized recipient to access a compatible transplant. 21 In conclusion, the SSO XR kits greatly improve HLAtyping of HLA-A and -B loci at an intermediate resolution, but rarely provide high resolution. Unfortunately, the improvement of the HLA-DRB1 locus typing is not satisfying. Consequently, there remains room for improvement with HLA-typing using this SSO method. More effective use of the full potential of the LABScan3D platform might reinforce interest in these kits even in the era of NGS for HLA-typing.
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